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PENILAIAN FARMAKOLOGI KE ATAS KESAN EKSTRAK DAUN 
SYZYGIUM POLYANTHUM (WIGHT) WALP. TERHADAP TEKANAN 
DARAH TIKUS DAN PARAMETER BERKAITAN 
 
ABSTRAK 
 
Daun Syzygium polyanthum (Wight) Walp. var. Polyanthum telah digunakan 
secara tradisional oleh masyarakat Melayu sebagai rawatan alternatif untuk penyakit 
darah tinggi. Bukti saintifik yang menyokong penggunaan tradisional ini masih 
terhad. Kajian ini menyiasat kesan ekstrak air (AESP) dan ekstrak “residual” 
metanol (met-AESP) bagi daun S. polyanthum ke atas tekanan darah tikus dan 
parameter berkaitan. Kedua ekstrak telah diberikan secara oral kepada tikus “Wistar-
Kyoto” yang mempunyai tekanan darah biasa dan kepada tikus “Spontaneously 
Hypertensive” (SHR), kemudian tekanan darah sistolik diawasi dalam tempoh 24 
jam. Seterusnya, kedua ekstrak telah diberikan setiap hari secara oral untuk 3 
minggu kepada SHR, kemudian tekanan darah sistolik diawasi selama 3 minggu. 
Dalam kajian seterusnya, kedua ekstrak telah diberikan secara suntikan ke dalam 
salur darah vena WKY dan SHR yang disuntik pelali, kemudian, tekanan darah 
purata arteri, sistolik, dan diastolik dan juga kadar jantung direkodkan selama 20 
minit. Dalam kajian berikutnya, kedua ekstrak telah ditambah pada torasik aorta 
yang diambil daripada WKY dan SHR yang telah dikontraksi oleh fenilefrin (1 µM) 
dan serotonin (10 µM). Kemungkinan penglibatan reseptor autonomik dan nitrik 
oksida dalam mediasi penurunan tekanan darah dan pengenduran salur darah oleh 
kedua ekstrak telah disiasat menggunakan penyekat yang berkaitan reseptor 
nikotinik- dan muskarinik-asetilkolin, α- dan β-adrenergik, dan nitrik oksida. 
Penyaringan bahan kimia tumbuhan, kromatografi gas spektrometri jisim, dan 
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kromatografi cecair berkualiti tinggi dijalankan untuk memperoleh profil bahan 
kimia ekstrak. Ekstrak yang diberikan secara oral, sama ada sebagai dos akut atau 
dos harian yang berulang telah menurunkan tekanan darah sistolik tikus SHR 
dengan signifikan. Kedua ekstrak telah menunjukkan kesan penurunan tekanan 
darah yang signifikan selepas tiga minggu rawatan, tetapi permulaan kesan 
penurunan darah oleh met-AESP adalah lebih cepat berbanding AESP. Kedua 
ekstrak yang diberikan secara suntikan melalui saluran darah vena telah 
menyebabkan kesan penurunan tekanan darah, tetapi hanya AESP pada dos yang 
paling tinggi telah menyebabkan sedikit penurunan kadar jantung pada WKY dan 
SHR yang disuntik pelali. Kesan penurunan tekanan darah oleh met-AESP lebih 
bertahan lama berbanding AESP dalam tikus SHR yang disuntik pelali. Kedua 
ekstrak juga menyebabkan pengenduran salur darah pada aorta daripada WKY dan 
SHR dengan kesan yang setara. Penurunan tekanan darah dan kadar jantung, serta 
kesan pengenduran salur darah oleh AESP dicadangkan sebahagiannya melibatkan 
reseptor α-adrenergik, sementara penurunan tekanan darah dan pengenduran salur 
darah oleh met-AESP sebahagiannya melibatkan reseptor muskarinik-asetilkolin dan 
β-adrenergik. Sebahagian dari kesan penurunan tekanan darah dan pengenduran 
salur darah oleh kedua ekstrak berkemungkinan melibatkan nitrik oksida. AESP 
mengandungi fenolik, tanin, flavonoid, saponin, dan kardiak glikosida; sementara 
met-AESP mengandungi fenolik, tanin, flavonoid, terpenoid dan resin. Gliserin, asid 
asetik, dan asid galik adalah bahan berpotensi di dalam AESP, sementara seselin, 
asid linolik, metil heksadekanoat, asid olik, dan asid galik adalah bahan berpotensi 
di dalam met-AESP yang berkemungkinan menyumbang kepada penurunan tekanan 
darah dan pengenduran salur darah oleh ekstrak ini. Kesimpulannya, kajian ini 
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menyokong penggunaan tradisional daun S. polyanthum sebagai rawatan alternatif 
untuk penyakit darah tinggi.  
PHARMACOLOGICAL EVALUATION ON THE EFFECT OF SYZYGIUM 
POLYANTHUM (WIGHT) WALP. LEAVES EXTRACT ON RAT’S BLOOD 
PRESSURE AND RELATED PARAMETERS 
 
ABSTRACT 
 
Syzygium polyanthum (Wight) Walp. var. Polyanthum leaves are 
traditionally consumed by the Malays as an alternative treatment for hypertension. 
However, the scientific evidence to support this claim is scarcely reported. The 
present study investigated the effects of aqueous (AESP) and residual methanolic 
extracts (met-AESP) of S. polyanthum leaves on rat’s blood pressure and related 
parameters. Both extracts were orally administered on Wistar-Kyoto (WKY) and 
Spontaneously Hypertensive rats (SHR), then systolic blood pressure (SBP) were 
monitored within 24 hours. Later, both extracts were daily administered via oral 
administration for 3 weeks in SHR, then the SBP were monitored within 3 weeks. In 
the subsequent study, both extracts were intravenously administered in anaesthetized 
WKY and SHR, then, mean arterial, systolic, and diastolic blood pressures, as well 
as the heart rate were recorded within 20 minutes. In the following study, both 
extracts were added on the phenylephrine (1 µM) - and serotonin (10 µM)-
contracted isolated thoracic aorta rings from WKY and SHR. Possible involvement 
of autonomic receptors and nitric oxide in mediating the blood pressure reduction 
and vasorelaxation by both extracts was investigated by using respective blockers 
for nicotinic-and muscarinic-acetylcholine, α- and β-adrenergic receptors, and nitric 
oxide. Phytochemical screening, gas chromatography mass spectrometry, and high 
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performance liquid chromatography were carried out to obtain phytochemical 
profiles of the extracts. The orally-administered extracts, either as an acute dose or 
repeated-dose significantly reduced blood pressure of conscious SHR. Both extracts 
showed significant hypotensive effects after 3-week treatment, but the onset of 
hypotensive effect by met-AESP was faster than AESP. Both of the intravenously-
administered extracts caused significant reduction in blood pressure, but only AESP 
at the highest dose caused mild reduction in heart rate of anaesthetized WKY and 
SHR. The blood pressure reduction by met-AESP was more sustained than AESP in 
anaesthetized SHR. Both extracts also caused vasorelaxation on aorta rings from 
WKY and SHR with comparable effects. The reductions in blood pressure and heart 
rate, and also vasorelaxation by AESP, were suggested to partly involve α-
adrenergic receptors, while the reduction in blood pressure and vasorelaxation by 
met-AESP partly involved muscarinic-acetylcholine and β-adrenergic receptors. A 
part of the reduction in blood pressure and the vasorelaxation effects by both 
extracts possibly involve nitric oxide. AESP contained phenolics, tannins, 
flavonoids, saponins, and cardiac glycosides; while met-AESP contained phenolics, 
tannins, flavonoids, terpenoids, and resins. Glycerine, acetic acid, and gallic acid 
were the potential compounds in AESP, while seselin, linoleic acid, methyl 
hexadecanoate, oleic acid, and gallic acid were the potential compounds in met-
AESP that possibly contributed to the reduction in blood pressure and 
vasorelaxation by these extracts. In conclusion, this study supported the traditional 
use of S. polyanthum leaves extracts as an alternative treatment for hypertension. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Hypertension: A worldwide problem 
 
Hypertension is a condition that describes a chronic elevation of blood 
pressure (Guyenet, 2006; Dugdale, 2011). It is a global dilemma with a worldwide 
prevalence of 40.0 % among adults aged 25 and above in 2008, as reported by the 
World Health Organization (WHO) (2014). Kearney and co-authors (2005) projected 
that, by the year 2025, the number of adults with hypertension will increase to a total 
of 1·56 billion. This projection has envisioned the future burden to be faced by the 
global population. Hypertension is a major risk factor for coronary heart disease and 
stroke. In fact, the WHO (2007) disclosed that 30.0 % from 58 millions of deaths 
worldwide in 2005 was due to various types of cardiovascular diseases with 
hypertension as a major underlying risk factor.  
 
Despite the high prevalence of hypertension, proper blood pressure control 
by hypertensive patients is still not achieved. In ‘National Health and Nutrition 
Examination Survey’ which was conducted in the United States, 47.5 % of those 
with high blood pressure did not have it controlled within year 2007 to 2010 (Go et 
al., 2013). Meanwhile, a recent report by the WHO (2014) stated that the number of 
people worldwide with uncontrolled hypertension rose from 600 million in 1980 to 
nearly 1 billion in 2008. With the alarming increase in the incidence of hypertension, 
the global control over the raised blood pressure is still unsatisfactory.  
2 
 
Likewise, this scenario is almost similar to the condition in Malaysia. Two 
national scale-studies conducted in Malaysia in year 1996 and in year 2006 have 
shown that the awareness, the treatment, and the control rates for hypertension were 
poor, in spite of the high incidence of hypertension (Lim et al., 2004; Rampal et al., 
2008). Lim and colleagues (2004) reported that only 26.0 % of those with high blood 
pressure and on anti-hypertensive medication in 1996 had a controlled range of 
blood pressure, while in 2006, Rampal and co-authors (2008) stated that the number 
only increased to 26.8 %. These findings indicated that hypertension still remains at 
stake both globally and locally.  
 
Even though the poor control of blood pressure maybe affected by some non-
compliance issues among hypertensive patients (Hassan et al., 2006), there also 
arises concerns regarding the efficacy of the available anti-hypertensive drugs, as 
well as, if there are needs to seek for more effective anti-hypertensive agents. In 
addition to the issue of efficacy, WHO (2013) has identified that the side effect of 
conventional anti-hypertensive drugs is one of the main factors that influence people 
into seeking for alternative traditional medicines. While some of the side effects are 
treatable by adding another medication, but some are incurable and may lead to a 
discontinuation of the prescribed medicines. The next major concern is the cost of 
anti-hypertensive drugs especially in countries where medicines are not subsidized. 
According to the American Heart Association, the estimated direct and indirect costs 
of hypertensive medication in the United States in year 2009 reached up to USD 
51.0 billion (Go et al., 2013).  
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1.2 Plant: A source of alternative anti-hypertensive medicines 
 
Since hypertension has remained as an unresolved problem, as a result, 
tremendous amount of researches have been conducted in looking for alternative 
anti-hypertensive medicines, especially from natural sources, such as plants. Most of 
the studies explored into traditional ethno-medicinal plants, which were evidenced 
over time. In fact, there are numerous conventional medicines at present such as 
papaverine (vasodilator), theobromine (diuretic), theophylline (mild diuretic), 
protoveratrins A and B (anti-hypertensive), rescinamine (angiotensin converting 
enzyme inhibitor), and reserpine (adrenolytic, anti-hypertensive) that were originally 
discovered through observations of traditional remedial methods of indigenous 
people (Aftab, 1995; Gilani and Atta-ur-Rahman, 2005; Lahlou, 2013). 
 
Since the search into traditional pharmacopoeia has led to successful 
discovery of modern anti-hypertensive medicines today, a lot of potential ethno-
medicinal plants have undergone various scientific investigations in proving the 
therapeutic claim to alleviate hypertension. As a preliminary step, various herbal 
preparations or extracts have been tested for their abilities to reduce blood pressure 
of rats (Ajay et al., 2007; Lima-Landman et al., 2007; Ameer et al., 2010a; Soncini 
et al., 2011). Furthermore, some of the investigations on the crude herbal 
preparations have led to bio-assay guided fractionation, leading to identification of 
the fractions that attribute to the utmost significant reduction in blood pressure of 
rats (Lima-Landman et al., 2007; Ameer et al., 2010b). Meanwhile, some other 
researches have successfully isolated the bioactive compounds that are responsible 
for the reduction in blood pressure of rats, such as eugenol (Lahlou et al., 2004b; 
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Interaminense et al., 2007), methyleugenol (Lahlou et al., 2004a), dodoneine 
(Ouedraogo et al., 2011), eucalyptol or 1, 8-cineolle (Lahlou et al., 2002b), α-pinene 
(El Tahir Kamal and Al-Ajmi, 2003), and artemetin (de Souza et al., 2011).  
 
1.3 Syzygium polyanthum (Wight) Walp. var. Polyanthum 
 
Although there are numerous claims made with regards to blood pressure 
lowering abilities by some Malay ethnomedicinal plants, it is for sure that, these 
claims entail for further scientific clarification. One of the ethno-medicinal plants 
that have been traditionally claimed by the Malays as an alternative treatment for 
hypertension is Syzygium polyanthum (Wight) Walp. var. Polyanthum (Noraida, 
2005; Yusuf, 2013). The shoots are commonly consumed as a fresh salad or ‘ulam’, 
while the decoction of S. polyanthum leaves is traditionally consumed as a 
hypertension remedy. This plant is popular among the Indonesians and the 
popularity is evidenced by the emergence of various S. polyanthum-based 
supplement products, such as drinks and herbal capsules in the market.  
 
Despite so, there is a dearth of scientific information that is available and 
accessible in the literature on the anti-hypertensive potential of S. polyanthum leaves. 
At the beginning of the present study, the only scientific rationale purporting on the 
potential of S. polyanthum leaves was indicated in a compilation book, entitled 
“Penelitian Tanaman Obat di Beberapa Perguruan Tinggi di Indonesia”. In this book, 
Hajar (1996), as cited in Sundari and co-authors (2000) reported that the infusion of 
S. polyanthum leaves caused a significant decrement in the blood pressure of Wistar 
rats, which were induced hypertensive by feeding with high-sodium diet.  
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In addition, previous researches have shown that there were a few potential 
compounds in the essential oil of S. polyanthum leaves, such as eugenol, eucalyptol, 
and α-pinene (Agusta, 2000; Arintawati, 2000; Kato et al., 2013) that might reduce 
the blood pressure.  Eugenol was demonstrated to cause immediate and dose-
dependent reduction in blood pressure and heart rate, in either anaesthetized or 
conscious rats (Lahlou et al., 2004b), and to exhibit vasorelaxation effects in rat’s 
(Damiani et al., 2003; Interaminense et al., 2007) and rabbit’s thoracic aorta 
(Nishijima et al., 1999), as well as on rat’s mesenteric vascular bed (Criddle et al., 
2003). Meanwhile, α-pinene was reported to cause reduction in blood pressure and 
increment of heart rate in non-anaesthetized rats (Menezes et al., 2010), and in 
urethane-anaesthetized rats (El Tahir Kamal and Al-Ajmi, 2003). Furthermore, 
eucalyptol was shown to cause an endothelium-dependent vasorelaxation on rat’s 
thoracic aorta (Lahlou et al., 2002b; Pinto et al., 2009); a blood pressure reduction in 
anaesthetized and in conscious normotensive rats (Lahlou et al., 2002b); and a 
reduction in myocardial contractility (Soares et al., 2005).  
 
Although these compounds might correlate to the proclaimed traditional use 
of S. polyanthum leaves as an alternative anti-hypertensive medicines, these studied 
compounds are compositions of the essential oil, which are sparingly soluble in 
water, and may not be present in the traditionally consumed S. polyanthum leaves 
decoction. Altogether, the traditional therapeutic claim on the use of S. polyanthum 
leaves decoction as an alternative anti-hypertensive medication still requires 
scientific validation by embracing its pharmacological effect on the cardiovascular 
system, especially on the blood pressure, and also by analyzing its phytochemical 
constituents.  
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1.4 Scope of study 
 
This study was divided into two important scopes, the phytochemical 
analysis and the pharmacological evaluation. The phytochemical analysis was 
instigated by a preliminary phytochemical screening for a rapid and convenient 
determination of the phytochemical groups present in S. polyanthum leaves extracts. 
A more comprehensive quantitative identification was then preceded by means of 
gas chromatography mass spectrometry (GCMS), and high performance liquid 
chromatography (HPLC). GCMS is commonly used for determination of volatile 
and semi-volatile constituents in plants (Al-Hashmi et al., 2013; Geetha et al., 2013; 
Sarikurkcu et al., 2013), while HPLC is used for separation of highly polar and large 
molecular weight materials that have very low volatility, and thus cannot be 
separated by gas chromatography (Scott, 2003). Thus, numerous researches have 
widely applied HPLC in the process of identification of chemical constituents in 
plants (Ameer et al., 2010b; Leeya et al., 2010; Alam et al., 2011; Praman et al., 
2011; Soncini et al., 2011; Shie and Lay, 2013). Gallic acid was introduced as a 
reference compound in this study as it was initially identified as the highest peak in 
the HPLC chromatograms of S. polyanthum leaves extracts, and therefore was 
quantified.  In addition, Har and Ismail (2012) have previously detected the presence 
of gallic acid in the methanolic extract of S. polyanthum leaves.  
 
The pharmacological evaluation on the effects of S. polyanthum leaves 
extracts was carried out using in vivo and in vitro methods. One of the in vivo 
approaches includes determination on the effects of orally-administered S. 
polyanthum leaves extracts on the blood pressure of conscious rats by using non-
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invasive tail-cuff method. This study mimicked the traditional oral route of 
administration in human, and the method was devoid of anaesthetic effect. Only the 
systolic blood pressure (SBP) was determined in this study while the mean arterial 
blood pressure (MAP) and diastolic blood pressure (DBP) readings were omitted 
since the point of readings are often indistinguishable due to the distraction that 
results from the motion and breathing artifacts. This predicament may explain the 
scarcity of data on mean arterial and diastolic blood pressures in other studies with a 
comparable design (Eddouks et al., 2005; Maghrani et al., 2005; Ichimura et al., 
2006; Ryu et al., 2008; Jaffri et al., 2011; Ng et al., 2011; Azizan et al., 2012; 
Thaweekhotr et al., 2012; Kaur et al., 2013; Tom et al., 2013).   
 
In addition, investigation on the hypotensive effect of plant extracts was 
usually employed on hypertensive rats models, such as Spontaneously Hypertensive 
rats (SHR) (Eddouks et al., 2005; Ichimura et al., 2006; Lima-Landman et al., 2007; 
Ryu et al., 2008; Ng et al., 2011; Azizan et al., 2012; Tom et al., 2013) or Nω-Nitro-
L-arginine methyl ester (L-NAME)-induced hypertensive rats (Lima-Landman et al., 
2007; Jaffri et al., 2011; Thaweekhotr et al., 2012). The normotensive Sprague-
Dawley rats (Kaur et al., 2013) or Wistar rats (Eddouks et al., 2005; Maghrani et al., 
2005; Ichimura et al., 2006; Lima-Landman et al., 2007; Jaffri et al., 2011; Ng et al., 
2011; Tom et al., 2013) were regularly used as the control group. By taking into 
account that hypertensive models should mimic the condition of hypertensive human 
beings, this study utilized the SHR model, which is the inbred of WKY with high 
blood pressure. The hypertensive state in SHR was constitutively imprinted in their 
genetic traits, and so, the high blood pressure has been maintained over generation 
(Okamoto and Aoki, 1963). In the present study, SHR and WKY as the 
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normotensive control, were treated with a single dose of extracts and the changes in 
SBP were monitored within 24 hours. These was followed by a 3-week study, where 
the SHR were treated with repeated-dose of extracts daily, and the changes in SBP 
were monitored over the 3-week period. 
 
On the other hand, another in vivo approach in the present study were to 
determine the direct effects of intravenously-administered S. polyanthum leaves 
extracts on blood pressure and heart rate of anaesthetized rats, via invasive arterial 
and venous cannulation. The blood pressure was measured via invasive method 
using blood pressure transducer that measured direct arterial pressure in the unit of 
voltage (Parasuraman and Raveendran, 2012). The blood pressure transducer 
allowed recordings of the direct blood pressure and calculated other parameters, such 
as MAP, SBP, DBP, and heart rate (HR). These parameters were utilized in various 
in vivo studies with comparable study design (Adeneye et al., 2006; Shih et al., 
2008; Senejoux et al., 2011).  
 
Since the measurement method is invasive, rats were anaesthetized prior to 
experiment. Anaesthesia provides a calm resting condition to rats, and at the same 
time, evades unnecessary stress. Previous invasive blood pressure measurement 
methods utilized barbiturates such as sodium pentobarbital (Testai et al., 2002; 
Lima-Landman et al., 2007; Shih et al., 2008; Kamkaew et al., 2011), thiopental 
(Adaramoye et al., 2009); thiobutabarbitural or inactin (Kamadyaapa et al., 2009); or 
a combination of inactin and sodium pentobarbital (Zhang and Tan, 1997). Other 
researchers opted for the use of urethane (Eno and Owo, 1999; El Tahir Kamal and 
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Al-Ajmi, 2003; Adeneye et al., 2006) or ketamine in combination with xylazine 
(Phillips et al., 2006; de Souza et al., 2011).  
 
According to the “Guidelines for the Use of Anesthetics, Analgesics and 
Tranquilizers in Laboratory Mammals”, provided by the University of Minnesota 
Board of Regents (2009), barbiturates are amongst the commonly used anaesthetics 
in laboratory animals for the relative ease of use. In fact, intraperitoneal injection of 
sodium pentobarbital at 50 mg/kg was reported to produce an anaesthetic effect on 
Crl: CD(BR) rats after 3.5 ± 1.4 min and the effect lasted for 95.0 ± 4.8 min (Field et 
al., 1993). Even though Field and colleagues (1993) have claimed that sodium 
pentobarbital caused a moderate to severe respiratory and cardiovascular depression, 
however, it was demonstrated in another study that the use of 50 mg/kg sodium 
pentobarbital did not significantly affect the baselines blood pressure of the 
anaesthetized SHR as compared to the conscious SHR (Chiueh and Kopin, 1978). In 
addition, the use of 50 mg/kg sodium pentobarbital did not significantly affect the 
DBP of normotensive Sprague-Dawley rats but significantly increased the HR in 
comparison with conscious rats (Fluckiger et al., 1985).  
 
Most importantly, it was demonstrated in some previous studies that the use 
of sodium pentobarbital at 50 mg/kg did not cause any significant difference in the 
magnitude of blood pressure and HR reductions by plant extracts in both 
anaesthetized and in conscious Wistar rats (Lahlou et al., 2002b; Lahlou et al., 
2004a). A more recent study has shown that sodium pentobarbital has provided the 
most stable hemodynamic values as compared to thiopental and urethane, and the 
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values are similar to the conscious rats (Zorniak et al., 2010). For the stated reasons, 
sodium pentobarbital was used in this study at a dose of 50 mg/kg body weight. 
 
Among the usually employed rat models using the intravenous route of 
administration includes anaesthetized normotensive rats such as Sprague-Dawley 
rats (Zhang and Tan, 1997; Shih et al., 2008; Ameer et al., 2010b) and Wistar rats 
(Lahlou et al., 2004a; Kamkaew et al., 2011; Senejoux et al., 2011; Soncini et al., 
2011), as well as on the anaesthetized hypertensive rats including of one-kidney, 
one-clip hypertensive rats (Nworgu et al., 2008); deoxycorticosterone acetate 
(DOCA)-salt-hypertensive rats (Lahlou et al., 2002a); L-NAME-induced 
hypertensive rats (Soncini et al., 2011); and SHR rats (Senejoux et al., 2011). 
 
The in vitro functional vascular study approach were used in the present 
study to determine the direct effects of S. polyanthum leaves extracts on the isolated 
rat’s thoracic aorta rings. The usage of isolated thoracic aorta rings in this set-up 
enabled the elucidation on the effect of S. polyanthum leaves extracts without the 
influence of intricate homeostatic control that usually exists in the body. Myograph 
was used to measure the force generated by a contracting muscle, such as trachea, 
gut, small, and large blood vessels. The generated force was converted into an 
electrical output that can be displayed and analyzed on a computer monitor in the unit 
of gram of contraction. Based on the changes of the force of contraction, the ability of 
drugs or plant extracts to relax or constrict the isolated blood vessel was evaluated.  
 
Some of the previous reports on the vasorelaxation ability of plants utilized 
various types of blood vessels which includes mesenteric, basilar, renal, tail, and 
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femoral arteries (Adaramoye et al., 2009; Kamkaew et al., 2011). However, the 
commonly used prototype for blood vessel in vasorelaxation studies of plant extracts 
is the thoracic aorta (Leeya et al., 2010; Kamkaew et al., 2011; Ouedraogo et al., 
2011). This study also utilized the rat’s thoracic aorta, specifically, the descending 
part that is located posteriorly from ascending thoracic aorta, and is adjacent to the 
vertebral column before it extends below the diaphragm and becomes the abdominal 
aorta (Figure 1.1). 
 
 
 
Figure 1.1: Thoracic aorta. Figure is adapted from Isselbacher (2007) 
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In fact, the ability of a plant extract to reduce rat’s blood pressure is often 
being associated with the vasorelaxation potential (Kamadyaapa et al., 2009; Ameer 
et al., 2010b; Sanchez-Salgado et al., 2010; Taiwo and Odeigah, 2010; Vergara-
Galicia et al., 2010; Soncini et al., 2011). Even the isolated compounds, such as 
eugenol (Lahlou et al., 2004b; Interaminense et al., 2007), methyleugenol (Lahlou et 
al., 2004a), dodoneine (Ouedraogo et al., 2011), eucalyptol (Lahlou et al., 2002b), 
and artemetin (de Souza et al., 2011), have shown both abilities to cause reduction in 
blood pressure in vivo and to cause vasorelaxation in vitro.  
  
Apart from investigation on the effects of S. polyanthum leaves extracts, 
studies on mechanism of actions are similarly important. Elucidation on the 
mechanism of reduction in blood pressure can be determined by in vivo method 
while the mechanism of vasorelaxation can be determined by in vitro method. 
Various antagonistic studies on specific receptors, or targeted to any systems that 
possibly mediate the reduction in blood pressure and vasorelaxation effects of the 
extract may be used in order to elucidate the pharmacodynamics of plant extracts. 
This study focused on the possible involvement of autonomic receptors. The 
autonomic receptors have long been held as one of the components that were 
responsible in the regulation and control of blood pressure (Purves et al., 2001; 
Franchini and Cowley, 2004; Jones et al., 2004).  
 
Nicotinic- and muscarinic-acetylcholine receptors, and α-and β-adrenergic 
receptors are among the autonomic receptors investigated in the present study. In 
conjunction, the respective receptor blockers such as hexamethonium, atropine, 
phentolamine, and propranolol, were employed to block the nicotinic- and 
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muscarinic-acetylcholine receptors, and α-and β-adrenergic receptors, respectively, 
according to a study protocol  by Zhang & Tan (1997). A few of the subtype-specific 
autonomic receptors, which includes the M3 subtype of muscarinic acetylcholine 
receptors; the α2 subtype of α-adrenergic receptors; and the β2 subtype of β-
adrenergic receptors; they are known to cause blood pressure reduction through 
vasorelaxation, mediated by the endothelium-derived relaxing factor, known as nitric 
oxide. Hence, this study was briefly extended into discovering any possible 
involvement of nitric oxide by using N-ω-nitro-l arginine methyl ester or L-NAME 
as a blocker according to a study protocol previously reported by Lahlou and co-
workers (2004a). The L-NAME blocks the endothelial nitric oxide synthase (eNOS), 
an enzyme used in the production of nitric oxide, a potent vasodilator.  
 
1.5 Objectives of study 
 
This study was aimed to achieve the following general and specific 
objectives. 
 
1.5.1 General objectives 
 
The general objective of the present study was to evaluate the effects of S. 
polyanthum leaves extracts on rat’s blood pressure and related parameters, and the 
possible mechanism of actions. 
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1.5.2 Specific objectives 
 
1. To determine the phytochemical composition in S. polyanthum leaves 
extracts (aqueous and methanolic). 
2. To determine the effects of orally-administered S. polyanthum leaves extracts 
on the systolic blood pressure of conscious Wistar-Kyoto and Spontaneously 
Hypertensive rats. 
3. To determine the effects of intravenously-administered S. polyanthum leaves 
extracts on the mean arterial, systolic, and diastolic blood pressures, and the 
heart rate of anaesthetized Wistar-Kyoto and Spontaneously Hypertensive 
rats. 
4. To determine the effects of S. polyanthum leaves extracts on the isolated 
thoracic aorta rings of Wistar-Kyoto and Spontaneously Hypertensive rats. 
5. To investigate the involvement of autonomic receptors in mediating the 
blood pressure reduction and the vasorelaxation effect by S. polyanthum 
leaves extracts. 
 
1.6 Research hypotheses 
 
1. S. polyanthum leaves extracts (aqueous and methanolic) consist of different 
phytochemical compositions. 
2. The orally-administered S. polyanthum leaves extracts cause reduction in 
systolic blood pressure of conscious Wistar-Kyoto and Spontaneously 
Hypertensive rats. 
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3. The intravenously-administered S. polyanthum leaves extracts cause 
reductions in mean arterial, systolic and diastolic blood pressures of 
anaesthetized Wistar-Kyoto and Spontaneously Hypertensive rats. 
4. S. polyanthum leaves extracts relaxed the isolated thoracic aorta rings from 
Wistar-Kyoto and Spontaneously Hypertensive rats. 
5. Autonomic receptors mediate the blood pressure reduction and the 
vasorelaxation effect by S. polyanthum leaves extracts. 
 
1.7 Justification of study 
 
The ability of S. polyanthum leaves extracts to reduce blood pressure was 
previously investigated in the normotensive, and in the induced-type of hypertensive 
rats. Hajar (1996), as cited in Sundari and co-authors (2000) showed that the 
intravenous administration of S. polyanthum leaves infusion caused significant 
reduction in blood pressure of Wistar rats which were induced hypertensive using a 
high-sodium diet. Sukrasno and colleagues (2010) reported that the oral 
administration of the aqueous extract of S. polyanthum leaves caused a significant 
reduction in mean arterial blood pressure of conscious normotensive Wistar rats. 
Recently, Ismiyati (2013) reported that the oral administration of ethanolic extract of 
S. polyanthum leaves caused a significant reduction in the increment of blood 
pressure by phenylephrine in conscious Wistar rats. Despite these studies, there was 
no reported study yet on the SHR, a chronic and stable model of hypertension that 
mimics the human essential hypertension (Doggrell and Brown, 1998). Therefore, 
the present study evaluated on the effects of S. polyanthum leaves extracts on few 
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blood pressure parameters such as the mean arterial, systolic, and diastolic blood 
pressures and the heart rate of SHR, with WKY as the normotensive control.  
 
In addition, there was no reported investigation yet on the mechanism of 
blood pressure reduction by S. polyanthum leaves extracts. In order to address this 
gap of information, the present study was the first report that elucidated on the 
vasorelaxation ability of the extracts, and also investigated on the involvement of 
autonomic receptors in mediating the reduction of blood pressure and the 
vasorelaxation effects by S. polyanthum leaves extracts. The in-depth understanding 
on the mechanism of actions is important in order to avoid the concomitant side 
effects following drugs or herbal interactions. 
 
Besides the lack of scientific investigation on the hypotensive effect by S. 
polyanthum leaves extracts, the phytochemical composition of S. polyanthum leaves 
extracts was also not extensively studied. Thus, the present study was extended to 
screen for the phytohemical constituents in S. polyanthum leaves extracts. The 
plant’s phytochemical profile is important to improve the quality of herbal products 
in future, and that should be based on consideration of any synergistic, additive, 
and/or nullifying effects of the bioactive constituent(s) in the herbal preparations. In 
the long-run, the quality of traditional medicine will be enhanced as emphasized by 
the WHO (2013) in its report, “WHO Traditional Medicine Strategy: 2013-2023”. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 Hypertension 
Hypertension is defined as the chronic elevation of blood pressure. It is a 
multi-factorial disease involving complex interactions between genetic and 
environmental factors (Lerman et al., 2005; Guyenet, 2006; Dugdale, 2011). 
According to the United States National Heart, Lung, and Blood Institute (NHLBI) 
(2012) and the American Heart Association (2013), a person with a systolic blood 
pressure (SBP) of less than 120 mmHg and a diastolic blood pressure (DBP) of less 
than 80 mmHg is classified as “normal”. Further increment of blood pressure 
between 120 to 139 mmHg for SBP and between 80 to 89 mmHg for DBP is 
classified under the “Pre-Hypertension” category. Further increment of blood 
pressure between 140 to 159 mmHg for SBP and between 90 to 99 mmHg for DBP 
is classified under “Stage I Hypertension” category. When the blood pressure rises 
above or equal to 160 mmHg for SBP and above or equal to 100 mmHg for DBP, 
that person is classified under “Stage II Hypertension” category. If blood pressure 
rises above 180 mmHg for SBP and 110 mmHg for DBP, the situation is termed as 
“hypertension crisis” and an emergency treatment is necessary.  
 
In general, hypertension can be classified into primary and secondary 
hypertension. In primary hypertension, or also known as essential or idiopathic 
hypertension, no known cause can be identified. However, the risk for 
cardiovascular and renal diseases is increased (Houston, 2009b). Kaplan and Opie 
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(2006) stated that primary hypertension accounts for, as many as 95.0 % of all cases 
of hypertension. In contrast, the secondary hypertension results from various medical 
conditions such as chronic kidney disease, eclampsia, thyroid disease, coarctation of 
aorta, aldosteronism, pheochromocytoma, brain lesion, Cushing syndrome, and sleep 
apnoea (Lyerly and Goodfriend, 2009).  
 
In certain cases that usually affect elder people, only the systolic blood 
pressure is high. This condition is known as isolated systolic hypertension. In 
addition, the NHLBI (2012) indicated that pregnancy and a few medicines, such as 
corticosteroids for asthmatic patients, birth control pills, cold-relief products or 
hormone therapy for reducing menopause symptoms, may also raise the systolic 
blood pressure. 
 
2.1.1 Prevalence 
 
Hypertension is on the rise globally and locally. It is a global dilemma with a 
worldwide prevalence of 40.0 % amongst those aged 25 and above, in 2008 as 
reported by the WHO (2014). In Malaysia, the National Health and Morbidity 
Survey II (NHMS) conducted in 1996, have shown that 32.9 % or an estimated of 
2.6 million Malaysian adults, aged 30 and above were affected with hypertension 
(Lim et al., 2004). In accordance, NHMS III that was carried out in 2006, has 
revealed that the prevalence of hypertension among the similar age group had 
increased to 40.5 % (Rampal et al., 2008). Similarly, the high prevalence of 
hypertension between 26.8 % and 35.6 % was also recorded by smaller scale studies 
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conducted in Malaysia (Mohd Yunus et al., 2004; Narayan and Rashid, 2007; Akter 
et al., 2010).  
 
2.1.2 Risk factors 
 
There are a few interplayed risk factors for hypertension which include age, 
race or ethnicity, obesity, gender, level of education, and family history of 
hypertension. According to the NHLBI (2012), blood pressure tends to rise with age. 
About 65.0 % of Americans, aged 60 and above was affected with hypertension. 
Isolated systolic hypertension is the most common form of hypertension that affects 
the elderly, where about 2 out of 3 people, aged 60 and above were classified as 
having isolated systolic hypertension. Likewise, some local studies conducted in 
Malaysia also revealed that the potential to get hypertension also increases steadily 
with increasing age (Mafauzy et al., 2003; Mohd Yunus et al., 2004; Narayan and 
Rashid, 2007; Rampal et al., 2008; Akter et al., 2010). With increased age, the large 
arteries stiffen while the plaque builds-up, and in long-term, it increases the 
incidence of cardiac and vascular diseases. 
 
Although hypertension can affect anyone, however, race may play a role and 
it has been considered as one of the main factors for hypertension as stated by the 
NHLBI (2012). According to this statement, hypertension is more common among 
African American adults than in Caucasian or Hispanic American adults. In relation 
to these groups, African Americans tend to be affected with hypertension earlier; are 
often to have more severe hypertension; and are less likely than Caucasians to 
achieve target control levels with hypertension treatment. African Americans also 
20 
 
have higher rates than Caucasians of early death from hypertension-related 
problems, such as coronary heart disease, stroke, and kidney failure. On the other 
hand, the NHMS II reported that the prevalence of hypertension was high across the 
ethnic groups of Malay, Chinese, Indian and indigenous people (Lim et al., 2004). 
However, the prevalence of hypertension among the indigenous (34.3 %) and the 
Malays (33.5 %) slightly outnumbered the Chinese (33.1 %) and the Indians (30.8 
%), but were not statistically significant. Similar findings were reported in the 
subsequent NHMS III. The findings showed that Malays (41.3 %) had the highest 
prevalence of hypertension, followed by the Chinese (40.0 %) and the Indians (37.7 
%), but these percentages were not statistically significant (Rampal et al., 2008). In 
agreement, a smaller scale study conducted in a rural community in Mukim Dengkil, 
Selangor pointed out that there was no significant association between race and 
hypertension (Mohd Yunus et al., 2004). 
 
Overweight or obesity is also identified as a risk factor according to the 
NHLBI (2012). This is supported by a few other studies conducted in Malaysia that 
reported a significant association between obesity and hypertension (Narayan and 
Rashid, 2007; Latiffah et al., 2008). The NHMS III also revealed  that hypertension 
increased with the increase of body mass index, whereby obese individuals were 
eight times more likely to develop hypertension (Rampal et al., 2008). Obesity 
increases with increasing age, and so, increases the chance of getting hypertension 
(Akter et al., 2010). However, a study by Mohd Yunus and colleagues (2004) in a 
rural community in Mukim Dengkil, Selangor found that there was no significant 
association between hypertension and obesity. 
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Meanwhile, it is debatable if gender is one of the risk factors for 
hypertension. A few studies conducted in Malaysia reported that there was no 
significant difference between male and female in getting hypertension (Mafauzy et 
al., 2003; Latiffah et al., 2008). However, in the NHMS II, female had higher 
prevalence of hypertension as compared to male (Lim et al., 2004). This finding is in 
agreement with the smaller scale studies conducted in Malaysia (Mohd Yunus et al., 
2004; Narayan and Rashid, 2007). On contrary, in the NHMS III, the male 
Malaysians aged 15 to 49 years old, had higher prevalence of hypertension as 
compared to female of similar range of age; meanwhile, female Malaysians, aged 50 
years old and above had higher prevalence of hypertension as compared to male of 
similar range of age (Rampal et al., 2008). This finding has indicated that, with the 
increment of age in female, their chances to develop hypertension increases. In fact, 
this finding was in corroboration with the report by the US NHLBI (2012) which 
pointed for men before the age of 45 are more likely to have hypertension than 
women. Interestingly, the condition is more likely to affect women than men after 
the age of 65. This is supported by Hart and Charkoudian (2014) who suggested that 
young women are relatively protected against the risk of hypertension due to greater 
peripheral vasodilator influences compared to young men and older people; 
however, this protective effect eventually is lost at menopause.  
 
Interestingly, education level is also identified as a risk factor. There is an 
inverse relationship between hypertension with an increased level of education 
(Narayan and Rashid, 2007; Latiffah et al., 2008; Rampal et al., 2008). Besides 
education, family history of hypertension also increases the prevalence of 
hypertension. Individuals with family history of hypertension were twice likely to 
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develop hypertension, as compared to those who were not (Rampal et al., 2008). 
Other than that, unhealthy lifestyle habits, such as excessive salt consumption, 
alcohol consumption, lack of potassium in diet, lack of physical activity, and 
smoking, may also raise the risk for hypertension (Rampal et al., 2008).  
 
2.1.3 Pathogenesis 
 
There are various pathophysiologic factors that contribute to the development 
of hypertension, including of genetics, environmental, neural, renin-angiotensin-
aldosterone system (RAAS), and altered vascular-related functions (Oparil  et al., 
2003; Gavras, 2009). Nevertheless, the relative roles of each of these factors in 
contributing to the development of hypertension may differ between individuals.  
 
2.1.3    (a) Genetics  
 
Several population-based studies have evidenced that genetics is one of the 
key factors for the genesis of hypertension (Hamet et al., 2002; Oparil  et al., 2003). 
Among the important findings in a few early epidemiological studies include: i) a 
highly significant correlation in blood pressure scores between parents and natural 
children (Biron et al., 1976), ii) a greater concordance of blood pressures in 
monozygotic identical twins than dizygotic twins (Feinleib et al., 1977), and iii) a 
greater similarity of blood pressure within families than between families (Longini et 
al., 1984). Likewise, recent findings further supported the role of genetics. It is 
widely accepted now that hypertension occurs more frequently in individuals with a 
positive family history of hypertension (Hamet et al., 2002), and, it was reported that 
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both paternal and maternal histories of hypertension were determinants of systolic 
and diastolic blood pressures of the offspring (Mitsumata et al., 2012).  
 
In some cases, hypertension may be caused by genetic mutations such as 
observed in patients with Liddle’s and Gordon’s syndromes (Hamet et al., 2002). 
The former syndrome is characterized by a defect in sodium channel, whereby it is 
continually activated, resulting in an increased sodium re-absorption. The latter 
syndrome is characterized by a defect in renal ion transport. These established forms 
of hypertension, even though are found to be rare in populations, has further 
affirmed the influence of genetics on the development of hypertension (Hamet et al., 
2002). 
 
Even though the development of hypertension is greatly influenced by 
genetics, it is also strongly affected by environmental factors (Hamet et al., 2002; 
Weder, 2005). Indeed, the interaction between gene-environmental factors 
determines the severity of blood pressure elevation and the timing of hypertension 
onset (Oparil  et al., 2003; Weder, 2005; Adrogué and Madias, 2007).   
 
2.1.3    (b) Environment 
 
A few environmental factors, such as high level of stress, high alcohol 
consumption, and high intake of sodium with low intake of potassium have been 
identified to contribute to the genesis of hypertension (Hamet et al., 2002; Oparil  et 
al., 2003; Weder, 2005). High level of stress has partly reasoned the great incidence 
of hypertension in low socio-economic groups, as demonstrated by Klag and co-
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workers (1991) in their study among the blacks of the United States of America. In 
addition, Calhoun and colleagues (1993) further demonstrated that normotensive 
blacks had a heightened sympathetic response to cold pressor test, a cardiovascular 
test performed by immersing the hand into an ice water container. By measuring the 
changes in blood pressure and heart rate, it was noticed that this repeated exposure to 
stress had increased the sympathetic outflow which led to the elevation of blood 
pressure.  
 
High alcohol intake also contributed to hypertension. A study conducted by 
Criqui and colleagues (1989) revealed that a high alcohol intake above the threshold 
level of 20 milliliters per day was associated with higher systolic and diastolic 
pressures. The finding indicated that there was a linear relationship of both systolic 
and diastolic blood pressures with alcohol consumption. 
 
Another pivotal environmental factors that contribute to pathogenesis of 
hypertension is the long-term dietary intakes of high sodium and low potassium 
(Weder, 2005; Adrogué and Madias, 2007). A worldwide epidemiological study, 
known as ‘The International Study of Salt and Blood Pressure’ or INTERSALT, 
which was conducted across 52 populations in year 1988 demonstrated a positive 
and linear relationship between 24-hour sodium excretion with blood pressure in 48 
populations (Stamler, 1997). The INTERSALT study also showed that, in 4 remote 
areas where the populations consumed relatively low sodium and high potassium 
intakes, and with little, if any, alcohol consumption; these populations were virtually 
free of hypertension.   
 
